Beyond Air, Inc. (XAIR) Stock Ticker
Market factors today
Unlock the full XAIR picture
About Beyond Air, Inc.
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
XAIR stock facts
| Ticker symbol | XAIR |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Medical - Devices |
| Market cap | $1.9M |
| CEO | Robert Goodman |
| Employees | 54 |
| Headquarters | Garden City, NY, US |
| IPO date | 2018-06-12 |
| Website | www.beyondair.net |
What you can see for XAIR on Tickr
Live XAIR price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the XAIR report.
Rankings
FAQ
What is the ticker symbol for Beyond Air, Inc.?
The ticker symbol for Beyond Air, Inc. is XAIR, listed on the NASDAQ Capital Market.
What is XAIR?
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the…